BEAM THERAPEUTICS Business Summary

Beam Therapeutics Inc. (BEAM) is a clinical-stage biotechnology company pioneering a novel class of precision genetic medicines through its proprietary base editing technology. The company primarily generates revenue through strategic license and collaboration agreements, characterized by upfront payments, milestone-based incentives, and research and development reimbursements from partners such as Pfizer and Eli Lilly. Its business is segmented into two primary therapeutic franchises: Hematology, led by its flagship sickle cell disease candidate risto-cel (BEAM-101), and Genetic Diseases, which focuses on liver-targeted therapies like BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-301 for glycogen storage disease type Ia. In a competitive landscape dominated by CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, and Prime Medicine, Beam distinguishes itself as the market leader in base editing, offering a "molecular pencil" approach that enables precise single-base alterations without the double-strand DNA breaks typical of first-generation CRISPR-Cas9 "molecular scissors." The company was founded in 2017 by a distinguished trio of gene-editing pioneers: David R. Liu (Broad Institute/Harvard), J. Keith Joung (Massachusetts General Hospital), and Feng Zhang (Broad Institute/MIT). The leadership team is headed by CEO John Evans, a former executive at Agios Pharmaceuticals, alongside President Giuseppe Ciaramella, Ph.D. (formerly of Moderna), Chief Financial Officer Sravan Emany (formerly of Ironwood Pharmaceuticals), and Chief Technology Officer Manmohan Singh, Ph.D. (formerly of Takeda). Beam’s strategic direction is further guided by a high-profile Board of Directors featuring industry veterans like John Maraganore, Ph.D. (founding CEO of Alnylam), and Chirfi Guindo (Merck). The company maintains a robust institutional investor base, including ARCH Venture Partners, F-Prime Capital, GV (Google Ventures), and ARK Investment Management, supporting a cash runway that extends into 2029 as it transitions toward potential commercialization.